Skip to main content

Table 3 Univariate analysis of factors associated with long-term outcomes (n = 44)

From: Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia

Items N 3-year-OS(%) P 3-year-EFS(%) P 3-year-CIR P
Sex    0.954   0.643   0.643
 Female 19 77.2% ± 10.2%   66.2% ± 11.4%   23.9% ± 10.6%  
 Male 25 72.3% ± 10.0%   63.0% ± 10.9%   33.0% ± 10.7%  
WBC(× 109/L)    0.865   0.512   0.527
 < 50 23 82.6% ± 7.9%   70.7% ± 10.4%   25.0% ± 9.9%  
 ≥ 50 17 66.8% ± 15.0%   57.0% ± 13.9%   31.2% ± 13.2%  
Haplo-HSCT    0.87   0.881   0.881
 No 7 85.7% ± 13.2%   42.9% ± 31.0%   57.1% ± 31.0%  
 Yes 37 73.0% ± 7.9%   65.6% ± 8.2%   26.4% ± 7.7%  
Age(years)    0.131   0.52   0.532
 < 10 24 87.3% ± 6.9%   64.5% ± 11.9%   31.4% ± 11.6%  
 ≥ 10 20 60.0% ± 12.0%   61.4% ± 11.8%   28.6% ± 11.1%  
MRD + at pre-HSCT    0.001   0.001   0.001
 No 29 89.7% ± 5.7%   81.4% ± 7.6%   11.7% ± 6.4%  
 Yes 15 48.5% ± 13.8%   34.3% ± 13.3%   59.0% ± 13.8%  
CNS infiltration    0.175   0.087   0.087
 No 37 78.3% ± 7.5%   68.1% ± 8.7%   23.9% ± 8.2%  
 Yes 7 57.1% ± 18.7%   42.9% ± 18.7%   57.1% ± 18.7%  
AF9    0.312   0.234   0.233
 No 34 78.5% ± 8.0%   68.7% ± 9.1%   25.6% ± 8.7%  
 Yes 10 60.0% ± 15.5%   50.0% ± 15.8%   40.0% ± 15.5%  
EVI1 Expression    0.612   0.969   0.949
 No 36 71.4% ± 8.4%   63.9% ± 8.5%   27.8% ± 8.0%  
 Yes 8 87.5% ± 11.7%   70.0% ± 18.2%   30.0% ± 18.2%  
FLT3-ITD mutations    0.737   0.392   0.39
 No 37 75.9% ± 7.6%   65.9% ± 8.7%   28.8% ± 8.4%  
 Yes 7 68.6% ± 18.6%   57.1% ± 18.7%   28.6% ± 17.1%  
1 cycle to CR    0.100   0.004   0.003
 No 17 64.2% ± 11.8%   37.3% ± 12.5%   50.9% ± 12.9%  
 Yes 27 80.7% ± 90.0%   82.6% ± 8.1%   13.7% ± 7.5%  
MRD- after 2 cycles    0.305   0.199   0.205
 No 21 70.2% ± 10.2%   54.9% ± 11.3%   40.4% ± 11.2%  
 Yes 23 82.6% ± 7.9%   77.4% ± 8.9%   13.9% ± 7.5%  
II-IV aGVHD    0.076   0.012   0.011
 No 32 83.2% ± 6.9%   74.7% ± 8.6%   22.3% ± 8.3%  
 Yes 12 43.8% ± 20.2%   37.5% ± 15.3%   45.8% ± 15.7%  
cGVHD    0.187   0.442   0.428
 No 28 69.5% ± 9.2%   61.0% ± 10.0%   28.3% ± 9.3%  
 Yes 16 83.3% ± 10.8%   70.0% ± 12.9%   30.0% ± 12.9%  
  1. OS overall survival, EFS event-free survival, CIR cumulative incidence of relapse, WBC white blood cell, Haplo-HSCT haploidentical haematopoietic stem cell transplantation, MRD + Minimal Residual Disease-positive, CNS central nervous system, aGVHD Acute graft versus host disease, cGVHD Chronic graft versus host disease, NA not available, EVI1 ecotropic viral integration site 1, FLT3-ITD fms-like tyrosine kinase 3 internal tandem duplication